Nissan Chemical Industries Limited

Nissan Chemical Corporation

Reprocell, Inc.

The University of Tokyo

Shunsuke Iwamoto

Katsuaki Miyaji

Norihisa Ishiwata

Takanori Nakamura

Yutaka Hirokawa

Kazufumi Yanagihara

Shingo Owada

Taito Nishino

Yukihiro Shigeta

Satoshi Nakano

Tsuneo Watanabe

Hirofumi Ota

Masato Horikawa

Toshihiko Kamiyama

Takuya Nishimura

Akio Yamamoto

Keiji Takahashi

Takahiro Kishioka

Yasuyuki Asai

Masao Yamamoto

Koji Eto

Hiromitsu Nakauchi

Keishi Hayashi

Masataka Minami

Miyuki Uni

Kazunori Kurihara

Koichiro Saruhashi

Makiko Umezaki

Daisuke Sakuma

Ayako Aihara

Koji Toyama

Shingo Umezawa

Takumi Mikashima

Kazuya Takeuchi

Makiko Yui

Mariko Ishida

Junko Takada

Yo Kishikawa

Katsuaki Myaji

Shingo Oowada

Kayoko Tsuji

The invention provides a ligand-bonded fiber in which a ligand having affinity for a cell membrane receptor is immobilized on a fiber precursor, and a cell culture substrate capable of repeating ex vivo amplification of a cell expressing a cell membrane receptor by using the ligand-bonded fiber.

Ligand-binding fiber and cell culture substrate using said fiber

Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A, Aand Ais a cyclohexane-1,4-diyl group or the like; each of L, Land Lis a methylene group or the like; each of Xand Xis O or NH; each of Rand Ris a cyano Chaloalkyl group or the like; and Ris an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Tricyclic compound and JAK inhibitor

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar, R, R, R, R, R, Rand Rare defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Method for expanding hematopoietic stem cells using heterocyclic compound

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells is provided, containing a compound represented by the formula (I): 

Heterocyclic compounds and expansion agents for hematopoietic stem cells

The object of the present invention is to provide a novel method for producing an isothiocyanate compound having a carboxyl group(s) by a reaction of the corresponding amino compound having a carboxyl group(s), thiocarbonyldiimidazole and a base, in one step with high purity. An amino compound having a carboxyl group(s) is reacted with thiocarbonyldiimidazole in a solvent in the presence of a base to obtain an isothiocyanate compound having a carboxyl group(s).

Method for producing isothiocyanate compound

A novel organic amine salt or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid having useful properties as a drug is provided. A novel organic amine or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid, a method for producing the organic amine salt or the salt with quaternary ammonium ion and a platelet increasing agent.

Organic amine salts of aminobenzoic acid derivatives and method for producing same

Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein Ris an aryl group fused to a saturated ring or the like, A, B, L, R, L, L, Y, L, Rand X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof. 

Fused heterocyclic compounds and thrombopoietin receptor activators

Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): 

Pyrazole compounds having therapeutic effect on multiple myeloma

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Heterocyclic compounds and thrombopoietin receptor activators

The present invention provides compounds useful for prevention, treatment or alleviation of diseases against which activation of the thrombopoietin receptor is effective. A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Amide compound and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators

A compound represented by the formula (I) (wherein R, R, Rand Rare as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Thiophene compounds and thrombopoietin receptor activators

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is ORSRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Growing community of inventors

Funabashi, Japan

Shunsuke Iwamoto